A retrospective analysis found no adverse events (AEs) in children receiving a live attenuated vaccine while on dupilumab or methotrexate treatment, challenging current recommendations. Researchers analyzed records of pediatric patients receiving these medications from 2017 to 2023 at a tertiary care center, with no AEs observed up to 6 months post-vaccination. Nine patients received the vaccine while on treatment, and no associated AEs were reported. The study suggests a need for larger, prospective studies to establish safe guidelines for administering live virus vaccines to children on immune-affecting medications. Limitations included a small sample size and retrospective data collection. The study was led by Julia R. Hughes and published in Pediatric Dermatology.
Source link
MMRV Safety Assessed in Children on Methotrexate, Dupilumab
